India is home to more than 100 million diabetics, and the demand for anti-diabetic drugs is on the rise -- the Rs 20,611 ...

Empagliflozin patent expiration in India leads to affordable treatment for diabetes, heart failure, and kidney disease.

USV launches empagliflozin and its combinations for diabetes care in India: Our Bureau, Bengaluru Wednesday, March 19, 2025, 12:40 Hrs [IST] USV, an Indian multinational healthcar ...

The uptick in the Morepen Labs share came after the company announced that it has rolled out ‘Empamore.’ Empamore is used to ...

Discover preclinical studies that indicate that empagliflozin reduces liver fat, improves liver function markers, and ...

Morepen Laboratories Limited announces the launch of Empamore, a game-changing treatment for Type 2 Diabetes Mellitus, Heart ...

Morepen Laboratories surged 8.90% to Rs 46.61 after the company launched Empamore, an affordable treatment for type 2 diabetes, heart failure, and chronic kidney disease in India.

Pharmaceutical company Morepen Laboratories Ltd on Monday (March 17) said it has launched a new treatment for Type 2 diabetes, heart failure, and chronic kidney disease. The drug, Empamore, is said to ...

There are early and suggestive data that GLP-1 drugs reduce alcohol cravings. A large cohort of people with alcohol use ...

There are early and suggestive data that GLP-1 drugs reduce alcohol cravings. A large cohort of people with alcohol use ...

Are you ignoring the early signs of kidney disease in diabetes? As diabetic kidney disease is on the rise, here’s what ...